Suchergebnisse - "Ganzel, Chezi"

PubPharm (7)

1

Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma : A multicentre retrospective study

enthalten in: British journal of haematology | 2023

von Shragai, T. | Magen, H. | Lavi, N. | +19

2

Measurable residual disease by flow cytometry in acute myeloid leukemia is prognostic, independent of genomic profiling

enthalten in: Leukemia research | 2022

von Ganzel, C. | Sun, Z. | Baslan, T. | +15

3

Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing

enthalten in: Nature medicine | 2021

von Cohen, Y. | Zada, M. | Wang, S. | +25

CommentIn: Nat Med. 2021 Mar;27(3):375-376. - PMID 33664491

4

Single-agent dabrafenib for BRAFV600E-mutated histiocytosis

enthalten in: Haematologica | 2018

von Bhatia, A. | Ulaner, G. | Rampal, R. | +9

5

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

enthalten in: Cancer discovery | 2016

von Diamond, E. | Durham, B. | Haroche, J. | +45

6

Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia

enthalten in: American journal of hematology | 2015

von Ofran, Y. | Leiba, R. | Ganzel, C. | +15

7

Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease

enthalten in: Blood | 2014

von Emile, J. | Diamond, E. | Hélias-Rodzewicz, Z. | +20

CommentIn: Blood. 2014 Nov 6;124(19):2901-3. - PMID 25377560

1
[1]